accelmed growth partners gp lp  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors accelmed growth partners gp lp check out list of companies and businesses related to accelmed growth partners gp lp find out accelmed growth partners gp lp address and contact details view other people related to accelmed growth partners gp lp  coworkers colleagues companions etc address  hachochlim street th floor herzliya pituach  israel companies related to accelmed growth partners gp lp cikcompany namepositioncompany addresscogentix medical inc de feltl road minnetonka  accelmed growth partners gp lp on the web persons related to accelmed growth partners gp lp  cogentix medical inc denamepositioncityaccelmed growth partners agp ltdherzliya pituachaccelmed growth partners lpherzliya pituachaccelmed growth partners management ltdherzliya pituachdavid w andersondirector montgomeryvilledavid w andersondirector montgomerydavid w andersondirector orangeburgdavid w andersondirector montgomeryvillecynthia f ansaripresident and ceo orangeburgkenneth w ansteydirector natickkenneth w ansteydirector orangeburgkenneth w ansteydirector orangeburgkenneth w ansteyminneapoliscarlos babinifremontcarlos babinieastonwarren l bielkedirector eden prairiewarren l bielkedirector orangeburgwarren l bielkeinterim ceo eden prariepolsky bruceorangeburgyoav m cohenchief financial officer orangeburgjames a dortadirector minnetonkakeith j c darraghvice president finance orangeburganderson davidorangeburggerald d erbvp marketing  sales fishersuri geigerherzeliaron hadanichief executive officer teaneckron hadanichief executive officer teaneckron hadanichief executive officer orangeburgron hadaniteaneckdarin hammersceo minnetonkadavid hanukaorangeburgdavid hanukavp research and development orangeburggideon hirschmannorangeburggideon hirschmann orangeburggideon hirschmannvice president of operations orangeburggideon hirschmannorangeburgrydzewski johnorangeburgwolf katherineorangeburgoneda katsumiorangeburgrobert killchairman president and ceo minnetonkalothar koobdirector peabodylothar kooborangeburglothar koobdirector orangeburgmark s landmanvp operations medical segment sharonmark s landmanvp disposables operations orangeburgmark s landmanvice president pell lewisorangeburgkoob lotharorangeburgthomas m olmsteadvp sales medical segment university heightskatsumi onedachairman of bod alpinekatsumi onedadirector orangeburgkatsumi onedadirector jitendra patelvp sales industrial segment norwoodjitendra patelvp industrial division orangeburgjitendra patelvp sales industrial segment kenneth h paulusdirector minnetonkacheryl pegusdirector orangeburglewis c pelldirector naticklewis c pellvicechairman of bod orangeburglewis c pelldirector orangeburglewis c pelldirector natickbruce polskyorangeburgbruce polskydirector orangeburgbrett reynoldssvp cfo treasurer st paulkevin h rochedirector minnetonkajohn j rydzewskiorangeburgjohn j rydzewskidirector costa mesajohn j rydzewskidirector orangeburgkenneth a sametdirector rockvillenachum shamirdirector austingary siegelvp finance orangeburgkenneth a spectorvp rd framinghamjames p staunerdirector lake forestjames a tracycfo newtonuroplasty incminnetonkajohn j wallacedirector walthamjohn j wallacedirector walthamjohn j wallacedirector cantonjohn j wallacedirector orangeburgjohn j wallacebielke warrenorangeburgsven wehrweindirector minneapoliskatherine wolforangeburgkatherine wolfexec vp corp dev  cfo orangeburgkatherine wolfexec vp corp dev  cfo orangeburghoward i zaubermandirector orangeburg homepage  accelmed vision  strategy  team  portfolio  contact    accelmed invests in private and public medical device companies around the world accelmed merges global businesses with promising medical device startups creating significant revenue growth accelmed’s platform model has proven to provide high returns to investors managers and entrepreneurs accelmed invests in private and public medical device companies around the world accelmed merges global businesses with promising medical device startups creating significant revenue growth accelmed’s platform model has proven to provide high returns to investors managers and entrepreneurs accelmed invests in private and public medical device companies around the world accelmed merges global businesses with promising medical device startups creating significant revenue growth accelmed’s platform model has proven to provide high returns to investors managers and entrepreneurs             merging medtech innovation with global commercial platforms    accelmed is an investment firm focused on value creation for medical device companies and technologies accelmed was founded in  by mori arkin and uri geiger and invests in small and midcap private and public companies with its proven track record and large team of accomplished investment professionals accelmed’s vision is to create leading medtech players by merging commercial platforms with small innovative growth companies predominantly from israel                       integrating commercial platforms with innovation and providing growth equity to foster significant value creation   accelmed brings its acumen in medical devices and its dominant presence in israel to the platform model which has already been implemented with great success under the platform model accelmed integrates innovative and marketready medical device technologies into existing commercial companies that are able to effectively distribute and commercialize the new products accelmed makes significant equity investments – or a combination of equity and debt – of between m and m per platform in certain cases in combination with its coinvesting partners investment can be increased to up to m we intend to acquire a significant interest in established medical device companies in the us europe and potentially in china with revenues in excess of m and which have an experienced direct sales force     proceeds of our investments will be used for both organic and inorganic growth through the acquisition and integration of innovative market ready medical device technologies identified and selected by accelmed and the platform company management the acquired israeli startups will serve as ongoing sources for costefficient rd as based on accelmed’s proven experience with israeli rd teams  they are not only innovative but also operate in a faster and more efficient way than their peers overseas     platform case studies endochoice – platform model case study the platform model modus operandi is best illustrated through the merger between peer medical an israeli company and developer of the full spectrum endoscope and endochoice a gastroenterology gi player in atlanta ga which had a solid commercial infrastructure but which lacked innovative products by merging peer into endochoice and the addition of working capital accelmed was able to transform endochoice from a commodity player into a cutting edge technology company the merger carried out in  led to endochoice’s emergence as a leading global gi player with sales above m in  more than doubled since the merger high doubledigit growth and a presence in more than  countries endochoice completed a successful ipo on june  and was sold to boston scientific in october          ois – platform model case study ois is another example of the successful deployment of accelmed’s platform model ois a californiabased ophthalmic imaging systems player acquired medivision the developer of an innovative retinal camera based on israeli defense technology the deal was financed and led by accelmed which held  of ois’s shares postmerger in  within two years ois was sold providing accelmed with an outstanding return                       team  mori arkin cofounder and chairman of the investment committee   mori arkin is one of israel’s most successful life science entrepreneurs he was the principal shareholder and chairman of agis industries  ltd from its establishment until its merger with perrigo in  agis one of the leading generic pharmaceutical companies in israel merged with usbased perrigo in march  in an  million transaction mr arkin has a degree in psychology and philosophy from the tel aviv university  dr uri geiger cofounder and managing partner   uri geiger brings extensive entrepreneurial management and investment knowhow having created and built many successful medical device enterprises until january  dr geiger served as ceo of exalenz bioscience ltd taseexen developer of an innovative breathbased technology for diagnosing liver and gastrointestinal disorders that was acquired from oridion systems today part of covidien and dr geiger took public in  he previously cofounded and was the ceo of galayor networks a developer of optical components sold in  to memscap euronext mems dr geiger is also the founding partner of dragon variation fund one of israel’s first hedge funds which was sold to migdal in  dr geiger worked on wall street during the s where he gained a broad understanding of capital markets and significant experience which he put to use after returning to israel in  dr geiger was formerly an adjunct professor at the recanati business school at tel aviv university where he lectured on private equity and venture capital he is the author of the books startup companies and venture capital tel aviv university press  and from concept to wall street financial times – prentice hall  he earned his doctorate from new york’s columbia university center for law  economics where he majored in global equity markets dr geiger served as a major in the israeli air force  dr irit yaniv md mba general partner   irit yaniv is an experienced and accomplished senior executive in the medtech industry and has held ceo positions with medical device companies impulse dynamics and metacure she plays an important role in leading accelmed’s early stage portfolio companies serving either as chairperson or as an active board member dr yaniv holds an md degree from the bengurion university and an mba from the recanati business school at tel aviv university  ilan ben oren partner  cto   mr ben oren brings more than  years’ experience in rd and management in the medical equipment field  mr ben oren assists accelmed’s portfolio companies in various development tasks prior to joining accelmed he served as the cto of exalenz bioscience ltd taseexen a developer of an innovative breathbased technology for diagnosing liver and gastrointestinal disorders prior to that mr ben oren held various positions from project manager to cto at oridion medical swxoridn earlier in his career he worked as a senior physicist at scitex ltd nasdaqscix and participated for five years in applied research at the laser center of hadassah hospital einkerem and the hebrew university mr ben oren is the author of more than  patents and patent applications in the field of medical technologies and electrooptics he holds a master’s degree in applied physics and the science of materials summa cum laude from the hebrew university of jerusalem  amir blatt partner   amir blatt brings wide experience in both the investment and medical device fields prior to joining accelmed mr blatt was an analyst at goren capital group advising investors ta companies and the government of israel on ma activity previously mr blatt held several sales and marketing positions with dover medical devices the jj distributor of diagnostics equipment in israel mr blatt graduated as a biotechnology engineer from the technionisrael institute of technology in haifa and holds an mba from the recanati school of management at tel aviv university  dr guy ohad chief medical officer   dr guy ohad is a radiologist with rich experience in the field of technology and medical devices his most recent positions include ceo at pop medical solutions a woman’s health company developing a minimal invasive device for treatment of pelvic organ prolapse before this he was vp of clinical and business development of the cr product line at orex a csh company former kodak in addition he served as a consultant to several medical device companies and served as clinical advisor at medica vc dr ohad holds a md from tel aviv university  dr susan alpert md phd chief regulatory officer   susan alpert formerly chief regulatory officer of medtronic is accelmed’s senior regulatory and clinical advisor she provides services to accelmed on a part time  basis working with accelmed portfolio companies as well as assisting accelmed in reviewing and evaluating investment opportunities dr alpert has held the positions of senior vice president and chief regulatory officer at medtronic until  and had a similar role at cr bard nysebcr before joining medtronic she held a number of positions with the fda including as director of the fda’s office of device evaluation dr alpert holds md and phd in infectious diseases from the nyc school of medicine   nadav shimoni associate   madav shimoni completed his medical studies at the ben gurion university bgu of the negev in beer sheva mr shimoni previously served as a project manager at an idf elite technological unit gaining significant experience in developing and designing complex mechanical elements in addition he is an anatomy teaching assistant at the medical school for international health msih – a collaboration between bgu and columbia university medical center he also engages in active volunteering work including medical workshops for populations in need  nir gilad analyst   nir gilad is involved with investment analysis and ongoing portfolio management prior to accelmed mr gilad worked at the israeli ministry of defense as a project finance analyst leading the national project of relocating the idf’s units to the south of israel previously he served as a financial analyst at the idf’s elite technology unit leading the unit’s economic analysis awarded with an honor for excellence mr gilad is an associate mentor at the global business studies program at coller school of management at tel aviv university and he holds a ba in economics and an mba both from tel aviv university  dr gilad rotem analyst   dr rotem holds an md degree from the technionisrael institute of technology in haifa israel as well as a bsc from tel aviv university in industrial engineering and another in biology in addition mr rotem was formerly professional longdistance triathlete who has participated in numerous international competitions mr rotem’s strong academic background and accomplishments in professional sports give him a unique perspective on health and athletics making him a valued asset to the accelmed team   executives network accelmed enjoys close collaboration with a network of seasoned executives who have built led and sold companies for billions of dollars these executives assist accelmed in identifying and analyzing potential opportunities and may serve in key leadership roles in future platform companies             the portfolio reflects a diversity of strategies employed in accelmed’s first and second funds   platforms  cogentix   cogentix nasdaqcgnt is a us based global urology focused company its main areas of activity are in overactive bladder oab advanced endoscopy systems and urethral bulking agents  httpwwwcogentixmedicalcom    endochoice sold   a global platformtechnology company focused on gastrointestinal gi endoscopy endochoice has merged with peer medical an israeli company which developed of a unique endoscopy technology to form a leading player in the gi industry endochoice is headquartered in alpharetta georgia with its rd center based in israel endochoice completed a successful ipo in june  and was sold to boston scientific in october  httpwwwendochoicecom  ophthalmic imaging systems sold   ophthalmic imaging systems ois is a leading provider of ophthalmic imaging and informatics solutions ois was the first investment of accelmed closed q and was sold two years later q to merge healthcare nasdaq merge httpwwwcanadianpharmacynet” target”blank”httpwwwcanadianpharmacynet  volcano sold   through its multimodality platform volcano corporation nasdaq volc is the global leader in intravascular imaging for coronary peripheral and physiology applications accelmed took a role of an active investor in the company which contributed to a successful acquisition by philips only a few months later httpwwwvolcanocorpcom   targeted innovation  corvia   corvia is developing the first transcatheter device to treat congestive heart failure chf the company’s innovative iasd™ interatrial shunt device system is designed to relieve increased left atrial pressure httpcorviamedicalcom  valcare medical   valcare medical was founded in  and is dedicated to designing developing and commercializing devices and accessories for minimally invasive treatment of heart valve disease httpwwwvalcaremedicalcom  digma   digma medical is an exciting new medical device startup that is focused on developing innovative solutions to metabolic diseases  sonivie   sonivie is developing an advanced denervation solution to treat pulmonary hypertension   incubator  eximo medical   eximo medical ltd is an early stage startup company founded in  the company is developing a novel medical device based on a single use hybrid catheter for various medical applications that require precise and safe material removal these applications have substantial and growing markets httpwwweximomedicalcom  memic   memic innovative surgery ltd is an early stage robotic company that develops an innovative surgical robot the surgical robot is based on a novel design which enables intuitive control and a new surgical approach for laparoscopic procedures  nitinotes   nitinotes is developing advanced nonsurgical bariatric solutions  revamp   revamp is offering an innovative temporary catheter for acute heart failure ahf primarily targeting diuretic resistance patients   venture capital  cartiheal   cartiheal is the developer of proprietary biocompatible and biodegradable offtheshelf implants for cartilage and bone regeneration cartiheal’s acellular implant is arthroscopically pressfit within a cartilage or osteochondral defect in a singlestage procedure and supports vessels formation followed by rapid invasion and adhesion of bone marrow mesenchymal stem cells the ce marked implant has significant loadbearing capability allowing patients faster rehabilitation httpwwwcartihealcom  endospan   endospan ltd is a vcbacked clinicalstage medical device startup developing a novel endovascular system intended to provide the next generation in endovascular aortic aneurysm repair evar endospan’s system aims to achieve a much smaller crossing profile compared with contemporary devices the system is intended for unilateral and purely percutaneous approach thus simplifying and significantly shortening the procedure httpwwwendospancom  nitiloop   nitiloop is dedicated to the development of cutting edge vascular support microcatheters our technology provides superior operatorcontrolled positioning and support in multiple applications nitiloop brings to the market ‘first choice’ products to overcome difficult lesions httpwwwnitiloopcom  picardia   picardia ltd is a medical device startup company developing a novel low profile catheter for the treatment of aortic stenosis the company’s proprietary technology is based on delivering mechanical impact for creating fractures in valve calcifications without injuring the surrounding soft tissue this treatment which only takes several seconds is intended to increase the valve effective orifice area without the need to replace the valve httpwwwpicardiacom   contact us office  madison avenue suite b new york ny  tel  israel office  hachoshlim st th floor herzliya pituach  tel  email infoaccelmedcom   accelmed growth partners lp top holdings whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active accelmed growth partners lp • herzliya pituach l • private equity how do i update this listing accelmed growth partners is based out of herzliya pituach whalewisdom has at least  dg filings in our database for accelmed growth partners the firm last filed a form d notice of exempt offering of securities on  the filing was for a pooled investment fund private equity fund the notice included securities offered of pooled investment fund interests summary dg insider form  form d  create email alert × email notification log in or signup to see more advanced email alert options such as selecting any type of sec form multiple filers or classes of filers and much more or to simply have an email sent to you whenever we receive a new f filing from accelmed growth partners lp enter your email address below and choose submit your email cancel contact info accelmed growth partners lp  hachoshlim street th floor herzliya pituach l     business phone  recent sec filings da filed on   filed on  sc d filed on  da filed on  d filed on  current dg holdings stock sector shares held market value rank source source date cogentix medical cgnt health care    d  schedule d and g events since  subscription required form   nonderivative insider transactions since  loading form d filings form d is a form to be used to file a notice of an exempt offering of securities with the securities and exchange commission form d contains basic information about the offering and the company form d filings filing date form type industry group securities offered total offering amount total amount sold total remaining  da pooled investment fund private equity fund pooled investment fund interests     da pooled investment fund private equity fund pooled investment fund interests     d pooled investment fund private equity fund pooled investment fund interests    other issuers in filings name address no other issuers related parties included in filings name address relationship agp ltd general partner of the gp accelmed growth partners subscription required promoter gp lp general partner accelmed growth partners subscription required promoter moshe arkin subscription required director uri geiger subscription required director elevate your investments try it for free   accelmed growth partners gp lp  insider monkey companies  see all hedge funds  see all insiders  see all institutional investors  see all click here to see all results for sorry no results has been found matching your query adblocker detected dear valued visitor we have noticed that you are using an ad blocker software although advertisements on the web pages may degrade your experience our business certainly depends on them and we can only keep providing you highquality research based articles as long as we can display ads on our pages to view this article you can disable your ad blocker and refresh this page or simply login we only allow registered users to use ad blockers you can sign up for free by clicking here or you can login if you are already a member home  insider trading  accelmed growth partners gp lp  profile accelmed growth partners gp lp profile insider purchases insider sales news affiliations large shareholder at cogentix medical inc cgnt  home hedge funds markets blog authors about us contact us privacy policy terms of use site map all text and design is copyright  koala guide llc all rights reserved accelmed growth partners lp  pooled investment fund accelmed growth partners formdscom  sec filings of fundraisings and investments in hedge funds private equity firms startups and growing companies formdscom newest filter local accelmed growth partners lp industry pooled investment fund see others in industry address  hachoshlim street  th floor herzliya pituach l phone  filings date filingtype reported sold incremental cash type exemptions link to raw filing  amended   other b c c sec link  amended   other b c c sec link  new   other b c c sec link directors and executives current and past name role gp lp general partner accelmed growth partners promoter agp ltd general partner of the gp accelmed growth partners promoter moshe arkin director uri geiger director accelmed growth partners lp raised  on january th  want to see morewant to find out who got funded and who’s funding the next big thing in real time all across the world tailored to your specific areas of focus deals per dayget access to the most exhaustive worldwide funding watch on the webcomprehensive funding informationknow about who invested in a company which sites covered the event the funding history etcexclusive insightsview original analytics such as most dynamic industries most active investors and morestay awareget emailed when deals critical to your business happen filter by region industry and topics of interestas seen onhave a loginsign inregister nowits freeuse your social accountor fill in the quick formregister nowpromise we wont spamsign invia your social accountvia your existing wgf accountremember meregister its freeforgot your passwordsign inforgot your passwordenter your email and we will send you your new passwordreset passwordthe worlds largest funding basedealsaccelmedgrowthpartnerslpsectiondealssubsectiondetailid   search deals by company name industry location investors search accelmed growth partners lp raised  on january th get alertedif accelmed growth partners lp gets fundedamountcompanyaccelmed growth partners lpinvestorsindustryfinancecountrycityisraelherzliya pituachkey peopleagp ltd general accelmed growth partners promoter gp lp accelmed growth partners promoter moshe arkin director uri geiger directordata sourceswwwsecgov  d  accelmed growth partners lp  filerdescriptionaccelmed growth partners lp revealed it has raised a m funding round january th  accelmed growth partners lp is a financespecialized firmplease note that all data is automatically extracted and errors can occurthe whogotfunded team has not necessarily reviewed the information in this page and has not determined if it is accurate and completeinaccurate data help us improve whogotfunded post a comment accelmed growth partners lp  who is raising money  sec filings of fundraisings and investments in hedge funds startups and private equity companies who is raising money accelmed growth partners lp funding details accelmed growth partners lp industry pooled investment fundcik number address  hachoshlim street th floor herzliya pituach phone number  latest news accelmed growth partners lp raised  from  investors on  accelmed growth partners lp filings datefiling typeofferedsoldremainingmin investmentinvest countexemption  exlusions amended form db c csec filingamended form db c csec filingnew form db c csec filing accelmed growth partners lp raised  in total directors and executives of accelmed growth partners lp key people in accelmed growth partners lp uri geigermoshe arkingp lp accelmed growth partnersagp ltd general accelmed growth partners last visited companies highside capital partners ii lp hamrod holmbogen llc haven real estate focus fund lp hedgeforum brevan howard multistrategy llc hedgeforum cfm llc  whoisraisingmoneycom daily updated news about investment into startups hedge funds and private equity companies accelmed growth partners lp sc d filing concerning cgnt on  whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active schedule d filed by accelmed growth partners lp total shares  subject company cogentix medical  view complete ownership history backtest filed as of date  event date  overall  ownership  reporting persons name solevoting power sharedvoting power soledispositive power shareddispositive power aggregateamount owned percentof class accelmed growth partners lp       accelmed growth partners gp lp       accelmed growth partners agp ltd       accelmed growth partners management ltd       uri geiger       view original filing on edgars raw filing contents txt   hdrsgml    accession number  conformed submission type sc d public document count  filed as of date  date as of change  group members accelmed growth partners agp ltd group members accelmed growth partners gp lp group members accelmed growth partners management ltd group members uri geiger subject company company data company conformed name cogentix medical inc de central index key  standard industrial classification electromedical  electrotherapeutic apparatus  irs number  state of incorporation de fiscal year end  filing values form type sc d sec act  act sec file number  film number  business address street   feltl road city minnetonka state mn zip  business phone  mail address street   feltl road city minnetonka state mn zip  former company former conformed name vision sciences inc de date of name change  filed by company data company conformed name accelmed growth partners lp central index key  irs number  state of incorporation e fiscal year end  filing values form type sc d business address street   hachoshlim street th floor city herzliya pituach state l zip  business phone  mail address street   hachoshlim street th floor city herzliya pituach state l zip  sc d  ddscdhtm sc d sc d cusip no a    d   page  of  pages       united states securities and exchange commission washington dc      schedule d rule d under the securities exchange act of  amendment no         cogentix medical inc name of issuer common stock  par value title of class of securities a  cusip number uri geiger accelmed growth partners lp  hachoshlim street th floor herzliya pituach israel   name address and telephone number of person authorized to receive notices and communications november   date of event which requires filing of this statement     if the filing person has previously filed a statement on schedule g to report the acquisition that is the subject of this schedule d and is filing this schedule because of §§ dle dlf or dlg check the following box  ☐     note schedules filed in paper format shall include a signed original and five copies of the schedule including all exhibits see §d for other parties to whom copies are to be sent        the remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page the information required on the remainder of this cover page shall not be deemed to be filed for the purpose of section  of the securities exchange act of  act or otherwise subject to the liabilities of that section of the act but shall be subject to all other provisions of the act however see the notes       cusip no a    d   page  of  pages         names of reporting persons irs identification nos of above persons entities only   accelmed growth partners lp      check the appropriate box if a member of a group see instructions a  ☐        b  ☒        sec use only        source of funds see instructions   oo      check if disclosure of legal proceedings is required pursuant to items d or e  ☐        citizenship or place of organization   cayman islands number of shares beneficially owned by each reporting person with             sole voting power    shares          shared voting power    shares          sole dispositive power    shares        shared dispositive power    shares    aggregate amount beneficially owned by each reporting person    shares    check if the aggregate amount in row  excludes certain shares see instructions  ☐      percent of class represented by amount in row        type of reporting person see instructions   pn    based upon  shares of common stock par value  per share of cogentix medical inc outstanding as of november   as provided by cogentix medical inc cusip no a    d   page  of  pages         names of reporting persons irs identification nos of above persons entities only   accelmed growth partners gp lp      check the appropriate box if a member of a group see instructions a  ☐        b  ☒        sec use only        source of funds see instructions   af      check if disclosure of legal proceedings is required pursuant to items d or e  ☐        citizenship or place of organization   cayman islands number of shares beneficially owned by each reporting person with             sole voting power    shares          shared voting power    shares          sole dispositive power    shares        shared dispositive power    shares    aggregate amount beneficially owned by each reporting person    shares    check if the aggregate amount in row  excludes certain shares see instructions  ☐      percent of class represented by amount in row        type of reporting person see instructions   pn    based upon  shares of common stock par value  per share of cogentix medical inc outstanding as of november   as provided by cogentix medical inc cusip no a    d   page  of  pages         names of reporting persons irs identification nos of above persons entities only   accelmed growth partners agp ltd      check the appropriate box if a member of a group see instructions a  ☐        b  ☒        sec use only        source of funds see instructions   af      check if disclosure of legal proceedings is required pursuant to items d or e  ☐        citizenship or place of organization   cayman islands number of shares beneficially owned by each reporting person with             sole voting power    shares          shared voting power    shares          sole dispositive power    shares        shared dispositive power    shares    aggregate amount beneficially owned by each reporting person    shares    check if the aggregate amount in row  excludes certain shares see instructions  ☐      percent of class represented by amount in row        type of reporting person see instructions   oo    based upon  shares of common stock par value  per share of cogentix medical inc outstanding as of november   as provided by cogentix medical inc cusip no a    d   page  of  pages         names of reporting persons irs identification nos of above persons entities only   accelmed growth partners management ltd      check the appropriate box if a member of a group see instructions a  ☐        b  ☒        sec use only        source of funds see instructions   oo      check if disclosure of legal proceedings is required pursuant to items d or e  ☐        citizenship or place of organization   cayman islands number of shares beneficially owned by each reporting person with             sole voting power    shares          shared voting power    shares          sole dispositive power    shares        shared dispositive power    shares    aggregate amount beneficially owned by each reporting person    shares    check if the aggregate amount in row  excludes certain shares see instructions  ☐      percent of class represented by amount in row        type of reporting person see instructions   oo    based upon  shares of common stock par value  per share of cogentix medical inc outstanding as of november   as provided by cogentix medical inc cusip no a    d   page  of  pages         names of reporting persons irs identification nos of above persons entities only   uri geiger      check the appropriate box if a member of a group see instructions a  ☐        b  ☒        sec use only        source of funds see instructions   af      check if disclosure of legal proceedings is required pursuant to items d or e  ☐        citizenship or place of organization   israel number of shares beneficially owned by each reporting person with             sole voting power    shares          shared voting power    shares          sole dispositive power    shares        shared dispositive power    shares    aggregate amount beneficially owned by each reporting person    shares    check if the aggregate amount in row  excludes certain shares see instructions  ☐      percent of class represented by amount in row        type of reporting person see instructions   in    based upon  shares of common stock par value  per share of cogentix medical inc outstanding as of november   as provided by cogentix medical inc cusip no a    d   page  of  pages   schedule d item  security and issuer this statement relates to the common stock  par value the common stock of cogentix medical inc the issuer having its principal executive offices at  feltl road minnetonka mn  item  identity and background this statement is being filed by a    accelmed growth partners lp the fund b    accelmed growth partners gp lp the gp c    accelmed growth partners agp ltd the gpgp d    accelmed growth partners management ltd the management company and e    uri geiger the controlling member and managing partner of the gpgp and the controlling shareholder and managing partner of the management company the persons named in this item  are referred to individually herein as a reporting person and collectively as the reporting persons the reporting persons have entered into a joint filing agreement dated as of the date hereof a copy of which is filed with this schedule d as exhibit  which is incorporated herein by reference pursuant to which the reporting persons have agreed to file this statement jointly in accordance with the provisions of rule dlk under the act the address of the principal business office of the reporting persons is accelmed growth partners lp  hachoshlim street th floor herzliya pituach israel  the principal business of the fund is to invest in medical device companies the principal business of the gp is to act as the sole general partner of the fund the principal business of the gpgp is to act as the sole general partner of the gp the principal business of the management company is to manage the fund the principal business of uri geiger is to manage the fund and affiliated entities during the five years prior to the date hereof none of the reporting persons have been convicted in a criminal proceeding or have been a party to a civil proceeding ending in a judgment decree or final order enjoining future violations of or prohibiting or mandating activities subject to federal or state securities laws or finding any violation with respect to such laws cusip no a    d   page  of  pages   the fund and the gp are cayman island exempted limited partnerships the gpgp and the management company are cayman island private limited companies uri geiger is an israeli citizen item  source and amount of funds or other consideration the fund purchased  shares the shares of common stock at  per share for an aggregate purchase price of  million pursuant to the purchase agreement as defined below the purchase agreement is more particularly described below under item  of this statement the working capital of the fund was the source of the funds for the shares no part of the purchase price of the shares was represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring holding trading or voting the shares item  purpose of transaction the fund acquired the shares for investment purposes depending on market conditions its continuing evaluation of the business and prospects of the issuer and other factors the fund and other reporting persons may dispose of or acquire additional shares of the issuer the issuer entered into a securities purchase agreement the purchase agreement with the fund on september   pursuant to the terms of the purchase agreement the fund purchased the shares from the issuer the share issuance on november   the closing date in connection with the purchase agreement on september   the issuer and lewis c pell pell entered into a note exchange agreement the note exchange agreement pursuant to the terms of the note exchange agreement the issuer and pell agreed to convert into shares of common stock all of the outstanding principal amount and accrued interest on certain notes held by pell the notes under the terms of the note exchange agreement the entire outstanding principal amount and all accrued interest on the notes was converted into  shares of common stock at a price per share of  on the closing date also pursuant to the note exchange agreement all of the outstanding warrants held by pell the warrants entitling pell to purchase shares of common stock were cancelled on the closing date in connection with the purchase agreement and the note exchange agreement on september   the fund and pell entered into a voting agreement the voting agreement pursuant to the terms of the voting agreement each of the fund and pell agreed to vote their shares of the issuers common stock for the other partys nominees to the issuers board of directors the board and each of the fund and pell are entitled to nominate two directors uri geiger and nachum shamir the initial nominees of the fund were appointed as members of the board on november   upon the closing of the share issuance the initial nominees of pell were pell and howard zauberman who were incumbent directors of the issuer prior to the closing of the share issuance as a result of the share issuance and the transactions contemplated by the note exchange agreement the transactions the fund and pell own or control a majority of the outstanding common stock as a result of the voting agreement the issuer qualifies as a controlled company under nasdaq rule c and is therefore exempt from certain corporate governance requirements under the nasdaq rules cusip no a    d   page  of  pages   in addition in connection with the purchase agreement the issuer entered into a registration rights agreement the registration rights agreement with the fund and pell on the closing date pursuant to which the issuer agreed upon demand by the fund to file a registration statement with the sec covering the resale of the shares issued pursuant to the terms of the purchase agreement and the note exchange agreement also under the purchase agreement the issuer agreed that following the closing date and upon demand by the fund the issuer will take all corporate actions necessary including taking commercially reasonable efforts to obtain stockholder approval to amend and restate the i amended and restated bylaws of the issuer and ii the amended and restated certificate of incorporation of the issuer the foregoing descriptions of the purchase agreement note exchange agreement the voting agreement and the registration rights agreement do not purport to be complete and are qualified in their entirety by the full text of the agreements copies of which are filed as exhibit  exhibit  exhibit  and exhibit  to this schedule d each of which is incorporated by reference into this item  except as set forth above none of the reporting persons has any present plans which relate to or would result in a    the acquisition by any person of additional securities of the issuer or the disposition of securities of the issuer b    an extraordinary corporate transaction such as a merger reorganization or liquidation involving the issuer or any of its subsidiaries c    a sale or transfer of a material amount of assets of the issuer or of any of its subsidiaries d    any change in the present board of directors or management of the issuer including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board e    any material change in the present capitalization or dividend policy of the issuer f    any other material change in the issuers business or corporate structure g    changes in the issuers charter bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any person h    causing a class of securities of the issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an interdealer quotation system of a registered national securities association cusip no a    d   page  of  pages   i    a class of equity securities of the issuer becoming eligible for termination of registration pursuant to section g of the securities exchange act of  or j    any action similar to any of those enumerated above item  interest in securities of the issuer a    the fund is the record owner of the shares as the sole general partner of the fund the gp may be deemed to own beneficially the shares as the sole general partner of the gp the gpgp may be deemed to own beneficially the shares the management company may be deemed to own beneficially the shares pursuant to a management agreement between the fund and the management company as the controlling member and managing partner of the gpgp and as the controlling shareholder and managing partner of the management company uri geiger may be deemed to own beneficially the shares each reporting person disclaims beneficial ownership of the shares other than those shares which such person owns of record the percentage of outstanding common stock of the issuer which may be deemed to be beneficially owned by each reporting person is set forth on line  of such reporting persons cover sheet such percentage was calculated based on  shares of common stock reported to be outstanding immediately after the transactions b    regarding the number of shares as to which such person has i      sole power to vote or to direct the vote see line  of cover sheets ii     shared power to vote or to direct the vote see line  of cover sheets iii    sole power to dispose or to direct the disposition see line  of cover sheets iv    shared power to dispose or to direct the disposition see line  of cover sheets c    except as set forth in item  above none of the reporting persons has effected any transaction in the common stock during the last  days d    no other person is known to have the right to receive or the power to direct the receipt of dividends from or any proceeds from the sale of equity securities of the issuer beneficially owned by any of the reporting persons e    not applicable cusip no a    d   page  of  pages   item  contracts arrangements undertakings or relationships with respect to securities of the issuer see items   and  above and item  below all of which are incorporated in this item  by reference item  material to be filed as exhibits   exhibitnumber    exhibit description     joint filing agreement dated november   by and among the reporting persons     securities purchase agreement dated september   by and between cogentix medical inc and accelmed growth partners lp incorporated by reference to exhibit  to the current report on form k of cogentix medical inc filed with the securities and exchange commission on september       note exchange agreement dated september   by and between cogentix medical inc and lewis c pell incorporated by reference to exhibit  to the current report on form k of cogentix medical inc filed with the securities and exchange commission on september       voting agreement dated september   by and between accelmed growth partners lp and lewis c pell incorporated by reference to exhibit  to the current report on form k of cogentix medical inc filed with the securities and exchange commission on september       registration rights agreement dated november   by and among cogentix medical inc accelmed growth partners lp and lewis c pell incorporated by reference to exhibit  to the current report on form k of cogentix medical inc filed with the securities and exchange commission on november   cusip no a    d   page  of  pages   signature after reasonable inquiry and to the best of my knowledge and belief i certify that the information set forth in this statement is true complete and correct date november     accelmed growth partners lp by   accelmed growth partners gp lp by   accelmed growth partners agp ltd by   s uri geiger name   uri geiger title   managing partner accelmed growth partners gp lp by   accelmed growth partners agp ltd by   s uri geiger name   uri geiger title   managing partner accelmed growth partners agp ltd by   s uri geiger name   uri geiger title   managing partner accelmed growth partners management ltd by   s uri geiger name   uri geiger title   managing partner s uri geiger uri geiger elevate your investments try it for free accelmed growth partners lp d filing  insider monkey companies  see all hedge funds  see all insiders  see all institutional investors  see all click here to see all results for sorry no results has been found matching your query adblocker detected dear valued visitor we have noticed that you are using an ad blocker software although advertisements on the web pages may degrade your experience our business certainly depends on them and we can only keep providing you highquality research based articles as long as we can display ads on our pages to view this article you can disable your ad blocker and refresh this page or simply login we only allow registered users to use ad blockers you can sign up for free by clicking here or you can login if you are already a member home  insider trading  latest d and g filings  d filing  filing details accession number  form type d filing publication date   filed by accelmed growth partners lp company cogentix medical inc nasdaqcgnt filing date  sec url d filing ownership summary please notice the below summary table is generated without human intervention and may contain errors please refer to the complete filing displayed below for exact figures name sole voting power shared voting power sole dispositive power shared dispositive power aggregate amount owned power percent of class                               filing cusip no a    d   page  of  pages      united states securities and exchange commission washington dc      schedule d rule d under the securities exchange act of  amendment no         cogentix medical inc name of issuer common stock  par value title of class of securities a  cusip number uri geiger accelmed growth partners lp  hachoshlim street th floor herzliya pituach israel   name address and telephone number of person authorized to receive notices and communications november   date of event which requires filing of this statement     if the filing person has previously filed a statement on schedule g to report the acquisition that is the subject of this schedule d and is filing this schedule because of §§ dle dlf or dlg check the following box  ☐     note schedules filed in paper format shall include a signed original and five copies of the schedule including all exhibits see §d for other parties to whom copies are to be sent        the remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page the information required on the remainder of this cover page shall not be deemed to be filed for the purpose of section  of the securities exchange act of  act or otherwise subject to the liabilities of that section of the act but shall be subject to all other provisions of the act however see the notes       cusip no a    d   page  of  pages        names of reporting persons irs identification nos of above persons entities only   accelmed growth partners lp     check the appropriate box if a member of a group see instructions a  ☐        b  ☒       sec use only       source of funds see instructions   oo     check if disclosure of legal proceedings is required pursuant to items d or e  ☐       citizenship or place of organization   cayman islands number of shares beneficially owned by each reporting person with             sole voting power    shares         shared voting power    shares         sole dispositive power    shares       shared dispositive power    shares   aggregate amount beneficially owned by each reporting person    shares   check if the aggregate amount in row  excludes certain shares see instructions  ☐     percent of class represented by amount in row       type of reporting person see instructions   pn   based upon  shares of common stock par value  per share of cogentix medical inc outstanding as of november   as provided by cogentix medical inc cusip no a    d   page  of  pages        names of reporting persons irs identification nos of above persons entities only   accelmed growth partners gp lp     check the appropriate box if a member of a group see instructions a  ☐        b  ☒       sec use only       source of funds see instructions   af     check if disclosure of legal proceedings is required pursuant to items d or e  ☐       citizenship or place of organization   cayman islands number of shares beneficially owned by each reporting person with             sole voting power    shares         shared voting power    shares         sole dispositive power    shares       shared dispositive power    shares   aggregate amount beneficially owned by each reporting person    shares   check if the aggregate amount in row  excludes certain shares see instructions  ☐     percent of class represented by amount in row       type of reporting person see instructions   pn   based upon  shares of common stock par value  per share of cogentix medical inc outstanding as of november   as provided by cogentix medical inc cusip no a    d   page  of  pages        names of reporting persons irs identification nos of above persons entities only   accelmed growth partners agp ltd     check the appropriate box if a member of a group see instructions a  ☐        b  ☒       sec use only       source of funds see instructions   af     check if disclosure of legal proceedings is required pursuant to items d or e  ☐       citizenship or place of organization   cayman islands number of shares beneficially owned by each reporting person with             sole voting power    shares         shared voting power    shares         sole dispositive power    shares       shared dispositive power    shares   aggregate amount beneficially owned by each reporting person    shares   check if the aggregate amount in row  excludes certain shares see instructions  ☐     percent of class represented by amount in row       type of reporting person see instructions   oo   based upon  shares of common stock par value  per share of cogentix medical inc outstanding as of november   as provided by cogentix medical inc cusip no a    d   page  of  pages        names of reporting persons irs identification nos of above persons entities only   accelmed growth partners management ltd     check the appropriate box if a member of a group see instructions a  ☐        b  ☒       sec use only       source of funds see instructions   oo     check if disclosure of legal proceedings is required pursuant to items d or e  ☐       citizenship or place of organization   cayman islands number of shares beneficially owned by each reporting person with             sole voting power    shares         shared voting power    shares         sole dispositive power    shares       shared dispositive power    shares   aggregate amount beneficially owned by each reporting person    shares   check if the aggregate amount in row  excludes certain shares see instructions  ☐     percent of class represented by amount in row       type of reporting person see instructions   oo   based upon  shares of common stock par value  per share of cogentix medical inc outstanding as of november   as provided by cogentix medical inc cusip no a    d   page  of  pages        names of reporting persons irs identification nos of above persons entities only   uri geiger     check the appropriate box if a member of a group see instructions a  ☐        b  ☒       sec use only       source of funds see instructions   af     check if disclosure of legal proceedings is required pursuant to items d or e  ☐       citizenship or place of organization   israel number of shares beneficially owned by each reporting person with             sole voting power    shares         shared voting power    shares         sole dispositive power    shares       shared dispositive power    shares   aggregate amount beneficially owned by each reporting person    shares   check if the aggregate amount in row  excludes certain shares see instructions  ☐     percent of class represented by amount in row       type of reporting person see instructions   in   based upon  shares of common stock par value  per share of cogentix medical inc outstanding as of november   as provided by cogentix medical inc cusip no a    d   page  of  pages  schedule d item  security and issuer this statement relates to the common stock  par value the common stock of cogentix medical inc the issuer having its principal executive offices at  feltl road minnetonka mn  item  identity and background this statement is being filed by a    accelmed growth partners lp the fund b    accelmed growth partners gp lp the gp c    accelmed growth partners agp ltd the gpgp d    accelmed growth partners management ltd the management company and e    uri geiger the controlling member and managing partner of the gpgp and the controlling shareholder and managing partner of the management company the persons named in this item  are referred to individually herein as a reporting person and collectively as the reporting persons the reporting persons have entered into a joint filing agreement dated as of the date hereof a copy of which is filed with this schedule d as exhibit  which is incorporated herein by reference pursuant to which the reporting persons have agreed to file this statement jointly in accordance with the provisions of rule dlk under the act the address of the principal business office of the reporting persons is accelmed growth partners lp  hachoshlim street th floor herzliya pituach israel  the principal business of the fund is to invest in medical device companies the principal business of the gp is to act as the sole general partner of the fund the principal business of the gpgp is to act as the sole general partner of the gp the principal business of the management company is to manage the fund the principal business of uri geiger is to manage the fund and affiliated entities during the five years prior to the date hereof none of the reporting persons have been convicted in a criminal proceeding or have been a party to a civil proceeding ending in a judgment decree or final order enjoining future violations of or prohibiting or mandating activities subject to federal or state securities laws or finding any violation with respect to such laws cusip no a    d   page  of  pages  the fund and the gp are cayman island exempted limited partnerships the gpgp and the management company are cayman island private limited companies uri geiger is an israeli citizen item  source and amount of funds or other consideration the fund purchased  shares the shares of common stock at  per share for an aggregate purchase price of  million pursuant to the purchase agreement as defined below the purchase agreement is more particularly described below under item  of this statement the working capital of the fund was the source of the funds for the shares no part of the purchase price of the shares was represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring holding trading or voting the shares item  purpose of transaction the fund acquired the shares for investment purposes depending on market conditions its continuing evaluation of the business and prospects of the issuer and other factors the fund and other reporting persons may dispose of or acquire additional shares of the issuer the issuer entered into a securities purchase agreement the purchase agreement with the fund on september   pursuant to the terms of the purchase agreement the fund purchased the shares from the issuer the share issuance on november   the closing date in connection with the purchase agreement on september   the issuer and lewis c pell pell entered into a note exchange agreement the note exchange agreement pursuant to the terms of the note exchange agreement the issuer and pell agreed to convert into shares of common stock all of the outstanding principal amount and accrued interest on certain notes held by pell the notes under the terms of the note exchange agreement the entire outstanding principal amount and all accrued interest on the notes was converted into  shares of common stock at a price per share of  on the closing date also pursuant to the note exchange agreement all of the outstanding warrants held by pell the warrants entitling pell to purchase shares of common stock were cancelled on the closing date in connection with the purchase agreement and the note exchange agreement on september   the fund and pell entered into a voting agreement the voting agreement pursuant to the terms of the voting agreement each of the fund and pell agreed to vote their shares of the issuers common stock for the other partys nominees to the issuers board of directors the board and each of the fund and pell are entitled to nominate two directors uri geiger and nachum shamir the initial nominees of the fund were appointed as members of the board on november   upon the closing of the share issuance the initial nominees of pell were pell and howard zauberman who were incumbent directors of the issuer prior to the closing of the share issuance as a result of the share issuance and the transactions contemplated by the note exchange agreement the transactions the fund and pell own or control a majority of the outstanding common stock as a result of the voting agreement the issuer qualifies as a controlled company under nasdaq rule c and is therefore exempt from certain corporate governance requirements under the nasdaq rules cusip no a    d   page  of  pages  in addition in connection with the purchase agreement the issuer entered into a registration rights agreement the registration rights agreement with the fund and pell on the closing date pursuant to which the issuer agreed upon demand by the fund to file a registration statement with the sec covering the resale of the shares issued pursuant to the terms of the purchase agreement and the note exchange agreement also under the purchase agreement the issuer agreed that following the closing date and upon demand by the fund the issuer will take all corporate actions necessary including taking commercially reasonable efforts to obtain stockholder approval to amend and restate the i amended and restated bylaws of the issuer and ii the amended and restated certificate of incorporation of the issuer the foregoing descriptions of the purchase agreement note exchange agreement the voting agreement and the registration rights agreement do not purport to be complete and are qualified in their entirety by the full text of the agreements copies of which are filed as exhibit  exhibit  exhibit  and exhibit  to this schedule d each of which is incorporated by reference into this item  except as set forth above none of the reporting persons has any present plans which relate to or would result in a    the acquisition by any person of additional securities of the issuer or the disposition of securities of the issuer b    an extraordinary corporate transaction such as a merger reorganization or liquidation involving the issuer or any of its subsidiaries c    a sale or transfer of a material amount of assets of the issuer or of any of its subsidiaries d    any change in the present board of directors or management of the issuer including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board e    any material change in the present capitalization or dividend policy of the issuer f    any other material change in the issuers business or corporate structure g    changes in the issuers charter bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any person h    causing a class of securities of the issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an interdealer quotation system of a registered national securities association cusip no a    d   page  of  pages  i    a class of equity securities of the issuer becoming eligible for termination of registration pursuant to section g of the securities exchange act of  or j    any action similar to any of those enumerated above item  interest in securities of the issuer a    the fund is the record owner of the shares as the sole general partner of the fund the gp may be deemed to own beneficially the shares as the sole general partner of the gp the gpgp may be deemed to own beneficially the shares the management company may be deemed to own beneficially the shares pursuant to a management agreement between the fund and the management company as the controlling member and managing partner of the gpgp and as the controlling shareholder and managing partner of the management company uri geiger may be deemed to own beneficially the shares each reporting person disclaims beneficial ownership of the shares other than those shares which such person owns of record the percentage of outstanding common stock of the issuer which may be deemed to be beneficially owned by each reporting person is set forth on line  of such reporting persons cover sheet such percentage was calculated based on  shares of common stock reported to be outstanding immediately after the transactions b    regarding the number of shares as to which such person has i      sole power to vote or to direct the vote see line  of cover sheets ii     shared power to vote or to direct the vote see line  of cover sheets iii    sole power to dispose or to direct the disposition see line  of cover sheets iv    shared power to dispose or to direct the disposition see line  of cover sheets c    except as set forth in item  above none of the reporting persons has effected any transaction in the common stock during the last  days d    no other person is known to have the right to receive or the power to direct the receipt of dividends from or any proceeds from the sale of equity securities of the issuer beneficially owned by any of the reporting persons e    not applicable cusip no a    d   page  of  pages  item  contracts arrangements undertakings or relationships with respect to securities of the issuer see items   and  above and item  below all of which are incorporated in this item  by reference item  material to be filed as exhibits   exhibitnumber    exhibit description     joint filing agreement dated november   by and among the reporting persons     securities purchase agreement dated september   by and between cogentix medical inc and accelmed growth partners lp incorporated by reference to exhibit  to the current report on form k of cogentix medical inc filed with the securities and exchange commission on september       note exchange agreement dated september   by and between cogentix medical inc and lewis c pell incorporated by reference to exhibit  to the current report on form k of cogentix medical inc filed with the securities and exchange commission on september       voting agreement dated september   by and between accelmed growth partners lp and lewis c pell incorporated by reference to exhibit  to the current report on form k of cogentix medical inc filed with the securities and exchange commission on september       registration rights agreement dated november   by and among cogentix medical inc accelmed growth partners lp and lewis c pell incorporated by reference to exhibit  to the current report on form k of cogentix medical inc filed with the securities and exchange commission on november   cusip no a    d   page  of  pages  signature after reasonable inquiry and to the best of my knowledge and belief i certify that the information set forth in this statement is true complete and correct date november     accelmed growth partners lp by   accelmed growth partners gp lpby   accelmed growth partners agp ltd by   s uri geigername   uri geigertitle   managing partneraccelmed growth partners gp lp by   accelmed growth partners agp ltd by   s uri geigername   uri geigertitle   managing partneraccelmed growth partners agp ltd by   s uri geigername   uri geigertitle   managing partneraccelmed growth partners management ltd by   s uri geigername   uri geigertitle   managing partner s uri geigeruri geiger hedge fund resource center how to beat the market by  percentage points why track hedge funds download a free edition why you should dump your hedge funds  things you didnt know about hedge funds hot topics apple aapl latest stock news  company profile warren buffett news  analysis  portfolio  stock picks biggest insider purchases  sales news  analysis  data screener google goog latest stock news  company profile microsoft msft latest stock news  company profile home hedge funds markets blog authors about us contact us privacy policy terms of use site map all text and design is copyright  koala guide llc all rights reserved